I. INTRODUCTION
Since the advent of single-cell organisms, with the introduction of a plasma membrane that can sequester the internal cellular contents, there has been a need for communication of information from the external to the intracellular milieu. In multicellular organisms, each cell must respond to both local and more distant signals for integrated actions to meet the needs of the organism. There are a number of mechanisms by which cells are able to receive information from the external milieu and integrate and transmit intracellular responses. One major sensing mechanism is via the superfamily of transmembrane receptors with intrinsic receptor tyrosine kinase (RTK) activity, which mediate a myriad number of cell activities. At least 58 RTKs have been identified to date (465) . The first member of the RTK superfamily to be identified was the epidermal growth factor receptor (EGFR).
The first EGFR ligand identified was the eponymous epidermal growth factor (EGF). EGF was originally identified by the Nobel laureate Dr. Stanley Cohen and his colleagues as the factor in a submaxillary gland extract that induced precocious eyelid opening and incisor eruption due to stimulation of epidermal growth and keratinization when injected into newborn mice (630) . Work by Cohen and Graham Carpenter subsequently identified that EGF's actions were mediated by binding to and activation of EGFR. Since its discovery in 1975, more than 60,000 articles related to EGFR have been published. EGFR (also known as ErbB1 or HER1) is a member of the ErbB/HER family of receptors, which are all single pass RTKs that derive their name from the discovery that the erythroblastosis tumor virus encodes an aberrant form of the human EGF receptor (ErbB) and that there are a family of human EGF receptors (HER) (19, 619) . The ErbB family also includes ErbB2 (HER2), ErbB3 (HER3), and ErbB4 (HER4). All four ErbBs have a common structure, with an extracellular ligand-binding domain, a single membranespanning region, a homologic cytoplasmic protein tyrosine lulin (BTC), heparin-binding EGF (HB-EGF), and epiregulin (EPR), which exhibit dual specificity in that they bind both EGFR and ErbB4. The third group is composed of the neuregulins (NRGs, also known as heregulins, HRGs), which form two subgroups based on their capacity to bind both ErbB3 and ErbB4 (NRG1 and NRG2) or only ErbB4 (NRG3 and NRG4) (222) . No ligands have been identified for ErbB2, which heterodimerizes with the other members of the ErbB family (267) . In addition, there has been a recent study suggesting that connective tissue growth factor (CTGF) can bind to and activate EGFR (452) .
EGFR ligands initially present as type I transmembrane proteins, with a "mature" soluble form released to cell matrix or cell culture medium following cleavage by metalloproteinases, especially members of the ADAM (a disintegrin and metalloproteinase) family of proteins (55, 127, 473) . The soluble peptides released extracellularly contain at least one characteristic EGF-like motif, defined by six spatially conserved cysteine residues that generate three peptide loops through the formation of disulfide bonds with the following interactions: C1-C3, C2-C4, C5-C6 (211, 483) . Less homology exists outside the essential cysteine and glycine residues required for the EGF-like conformation.
Proteolytic release of EGFR ligands represents an important regulatory step for receptor activation (246, 497) . However, many EGFR ligand precursors, including HB-EGF, TGF-␣, AREG, and BTC, may activate EGFR even when they are tethered to the plasma membrane, suggesting they may also function as juxtacrine factors (15, 236, 244, 512, 513, 533) . EGFR activation is increasingly recognized to mediate many signaling processes of hormones and other growth factors, through EGFR "transactivation." Receptor transactivation can occur either through regulated activation of metalloproteinase-dependent ligand release or through non-ligand-dependent receptor activation.
Following ligand binding to a single EGFR molecule, the bound EGFR will dimerize either with an additional EGFR molecule (homodimerization) or with another member of the ErbB family (heterodimerization). ErbB2 is the preferred heterodimerization partner. EGFR has also been reported to heterodimerize with receptors for hepatocyte growth factor (HGF), insulin-like growth factor (IGF)-I, and platelet-derived growth factor (PDGF) (42), but the biologic significance of these interactions remains unclear. The tyrosine kinase domains of both members of the receptor dimer are activated and autophosphorylate selected tyrosine residues in the cytoplasmic tail (638) (FIGURE 2). These phosphorylated residues then serve as docking sites for signaling protein complexes, including binding sites for Shc, Grb2, Grb7, Crk PLC-␥, SRC, PI-3K, protein phospha- tases-SHP1 and SHP2, and the E3 ubitquitin ligase Cbl. Other proteins, such as Stat1, Stat3, Stat5, and PLD, do not bind directly to EGFR but participate in signaling. Signaling pathways activated by EGFR include ras/raf/MEK/ERK, PI3K-Akt, p38, JNK, JAK-Stat, Src, small GTPases such as Rho and Rac, PLC-␥/Ca 2ϩ /PKC and PKD (some important signaling pathways are shown in FIGURE 3). In addition, posttranslational modifications by methylation of the extracellular domain of EGFR has been reported to reugulate EGFR function (73) .
Following ligand binding, the activated EGF receptors cluster in coated pits and are then endocytosed via clathrincoated vesicles (250). Cbl-mediated ubiquitination induces lysosomal degradation. However, different EGFR ligands may differentially regulate EGFR signaling and trafficking. For example, HB-EGF and BTC induce persistent receptor phosphorylation, ubiquitination, and degradation while TGF-␣ binding leads to transient EGFR phosphorylation, minimal ubiquitination, and almost complete recycling from endosomes, which has been suggested to be due to increased dissociation of TGF-␣ from the receptor in acid endosomes, leading to recycling of the unbound EGFR (466) . In addition to classic clathrin-mediated endocytosis, EGFR may also be endocytosed by non-clathrin-mediated mechanisms, including caveolae (27) . In this regard, knocking down clathrin completely inhibited EGF-mediated endocytosis but only partially inhibited BTC-and HB-EGFmediated endocytosis (216). There have also been studies indicating that ligand concentration is a determinant of the mode of endocytosis, with lower concentrations leading to clathrin-mediated endocytosis, with receptor recycling, and higher concentrations inducing clathrin-independent endocytosis, with persistent ubiquitination and receptor degradation (507) (508) (509) . A recent study further confirmed that Cbl and Grb2 binding to phosphorylated EGFR receptormediated ubiquitination displays a sharp threshold effect as a function of EGF concentration (301) .
Although endocytosis of EGFR was originally thought to terminate the signaling process (76) , there is now increasing evidence for continued signaling from endocytic vesicles, as well as subsets of internalized receptors in selected subcellular organelles. Inhibition of endocytosis has been reported in some, but not all, studies to alter ERK and PI-3K/Akt signaling (403, 508, 522, 568) . In addition to membraneassociated receptors, EGFR receptors have been identified in the nucleus and posited to serve as a transcription factor (206, 302, 314) . Nuclear translocation of the cytoplasmic tail of ErbB4 following successive cleavage by ADAM17 (TACE) and ␥-secretase and association with the WW domain protein YAP has been well described (16, 304) , and a nuclear entry mechanism for endocytosed EGFR has also been suggested (312) . In addition, translocation of EGFR to the mitochondria and association with the mitochondrial cytochrome c oxidase subunit II (CoxII) has also been reported (126) .
c-Src is the prototypical member of a family of non-receptor-mediated intracellular tyrosine kinases that mediate many cell functions (131) . c-Src is activated in response to EGFR activation and mediates a subset of its downstream actions. In addition, c-Src can phosphorylate EGFR at cytoplasmic residue Tyr845 even in the absence of ligand stimulation (90, 131).
EGFR activation is modulated by extracellular matrix, and specifically by interaction with integrin association with ECM. Some, but not all, studies have suggested that adhesion of cells to ECM can activate EGFR in a ligand-independent manner (12, 373) , while other studies have suggested that plating cells on laminin, fibronectin, or type I collagen can augment ligand-dependent EGFR activation (12) . Integrins can either interact directly with EGFR or within cell surface macromolecular complexes (527) . In some systems, the collagen-binding integrins have been shown to negatively regulate EGFR activation by binding and activating a specific tyrosine phosphatase (TCTP) (94, 341) , and ligand stimulation can dissociate EGFR from the collagen binding ␣3␤1 integrin. In addition, several studies have indicated that maximal and sustained EGFR activation is dependent on integrin ligation of ECM (527) .
A number of proteins have been identified that can modulate EGFR signaling pathways. Inhibitors of EGFR include mitogen-inducible gene-6, fibroblast growth factor receptor substrate 2␤, suppressor of cytokine leucine-rich repeats and immunoglobulin-like domain 1 (LRIG1). In this regard, LRIG1 has recently been shown to act as an inducible, negative feedback inhibitor of EGFR signaling (189, 279) . LRIG1 binds to the extracellular EGFR domain and promotes Cbl-mediated ubiquitination, followed by internalization and degradation (199) . In addition, LRIG1 is cleaved by ADAM17, and the soluble extracellular domain can inhibit ligand binding to EGFR (185) . In contrast, cytohesins 1-4, guanine nucleotide exchange factors (GEF) for ADP ribosylation factors of Ras-like GTPases, interact with the cytoplasmic tails of EGFR dimers and stimulate receptor autophosphorylation and activation (45). Cytohesins also augment EGFR ligand-binding efficiency (615) . In addition to EGFR-associated proteins that regulate receptor activity, there is increasing evidence for an important role for miRNAs to regulate EGFR expression, especially in cancers (203) . For example, miR-155 has been reported to directly suppress EGFR and other key drivers of breast tumor invasion and metastasis (388) . However, in miR-24 expressing breast cancer cells and breast tumors, EGFR was highly phosphorylated, while the expression levels of the tyrosine-protein phosphatase non-receptor type 9 (PTPN9) and receptor-type tyrosine-protein phosphatase F (PTPRF) were suppressed (133) . Increased cancer cell miR-10b in pancreatic ductal adenocarcinoma is a marker of disease aggressiveness, possibly due to its actions to enhance EGF stimulation of EGFR (406) . In glioblastoma, miR-148a augments EGFR activation through inhibition of the expression of MIG6, the EGFR regulator (264) . In non-small cell lung cancers (NSCLCs), miR-133a directly inhibits EGFR expression, leading to inhibition of cancer cell invasion and growth (579) .
II. ROLE OF EGFR IN DEVELOPMENT
EGFR activation is crucial for embryogenesis and organogenesis, and impairment of EGFR signaling during organogenesis may result in respective defect in different organs (FIGURE 4).
A. EGFR in Preimplantation Embryogenesis and Placental Development
Numerous studies have shown that EGFR along with its ligands, EGF and TGF-␣ in particular, are important for mammalian preimplantation embryogenesis (97, 545, 593, 594, 596, 602) . EGFR and its ligands, EGF and TGF-␣, are expressed in preimplantation embryos from the 4-to 8-cell stage, in the uterus, and in the oviduct (TGF-␣ only) (detailed review in Ref. 254) . Strong EGFR immunoreactivity has been detected in the apical cell surface of morula and blastocytes, which is distinct from its basolateral localization in the adult polarized epithelial cells but is close to the localization of EGF and TGF-␣ (58, 97, 602) . The simultaneous expression and colocalization of EGFR with its ligands at the preimplantation stage may indicate a need for maximum activation of EGFR through exposure to its ligands that can arise not only from autocrine activation but also from paracrine activation (EGF or TGF-␣ from oviduct or uterus) (254) .
Many studies have shown that EGF and/or TGF-␣ produce a stimulatory effect on in vitro mouse embryogenesis through increasing protein synthesis, cell number, and blastocyte expansion (detailed review in Refs. 210, 459, 630) , but EGF may also impose an inhibitory effect at higher concentrations (100 ng/ml) (184) . In addition, there may be stage-specific effects of EGF, with promotion of cleavage before the four-cell stage and regulation of differentiation after the morula stage (541) . Homozygous EGFR deletion (EGFR null) resulted in peri-implantation death due to degeneration of the inner cell mass in the CF-1 strain of mice. EGFR deletion in 129/Sv mice resulted in mid-gestational (E11.5) death due to a placental defect manifested by greatly reduced spongiotrophoblast layer and disorganized labyrinthine trophoblast with a reduced cell number, which indicates a pivotal role of EGFR in placental development, while C57BL/6 mice with EGFR deletion die at birth most likely due to lung immaturity and CD1, C3H, and MF1 strains with EGFR deletion can survive up to postnatal day 18 to 20 (P18 -P20), albeit with abnormalities in bone, brain, heart, and various epithelia such as the skin, hair follicles, and eyes (355, 503, 505, 546, 605) .
EGFR is expressed in the uterine stroma and plays a supportive role in embryogenesis by promoting uterine development, embryo implantation, and placental development. Uterine grafts derived from EGFR null pups have stunted growth and lack a proliferative response to estradiol stimulation compared with grafts from wild-type mice (223). During implantation, expression of EGFR and its ligands is observed in the uterus at the site of blastocyst attachment as well as on the surface of the implanting blastocyst (121, 552) . In this regard, HB-EGF, a ligand for both EGFR and ErbB4, may play a unique and essential role since HB-EGF null female mice have markedly impaired fertility due to partial implantation failure (611) . EGFR also regulates growth and differentiation of the placenta. EGFR mutant placentae of all genetic backgrounds exhibit a markedly reduced spongiotrophoblast layer (502) . Compared with the 129/Sv strain, 40 -50% of the mutant fetuses from C57BL/6, MF1, and C3H background can survive this placental defect due to their relatively large placenta size, indicating that the postnatal phenotypes occur independently of placental defects (502) . On the other hand, mice with a hypermorphic EGFR allele, Egfr Dsk5 (Dark skin-5 allele), have larger placentae with a more prominent spongiotrophoblast layer and increased expression of trophoblast glycogen cell-specific genes in all three mouse strains tested (C3H, C57BL/6J, 129/Sv). Interestingly, larger placentae did not necessarily promote embryo growth (112) . Therefore, a balanced EGFR signaling is required for proper embryogenesis.
B. EGFR in Organogenesis and Postnatal Development
Studies from EGFR null and waved-2 (wa2) mice that harbor a point mutation in EGFR gene with resultant loss of most of its tyrosine kinase activity reveal a complex role for receptor activation during embryonic and postnatal development (318, 355, 505, 546) . As noted above, all surviving EGFR null mice exhibit growth retardation and have multiple abnormalities (355, 503, 505, 546, 577, 605 ).
EGFR in lung development
EGFR is expressed in type II pneumocytes, and EGFR inactivation results in type II pneumocyte immaturity with impaired surfactant production and a decreased ability to prevent alveolar collapse (358, 505) . Lungs from EGFR null mice display reduced branching and deficient alveolization and septation with hypercellularity and thickened alveolar septae, resembling the morphology seen in neonatal respiratory distress syndrome (358, 503, 505) .
EGFR in heart development
Both EGFR null and wa2 mice develop thickened and hypercellular semilunar (SL, pulmonary and aortic) cardiac valves, similar to what has been described in HB-EGF deletion mice, suggesting that HB-EGF/EGFR signaling is required for the differentiation of valve mesenchymal cells within the valve leaflets (245, 504). On the other hand, cardiac hypertrophy was seen in mice with elevated levels of EGFR expression in the heart (504).
EGFR in central nervous system development
The central nervous system (CNS) is composed of two main cell types: neurons and glial cells. Glial cells are also known as "supporting cells" for neurons and include astrocytes, oligodendrocytes, and microglia. Rodent neurogenesis begins around E9, and strong EGFR expression can be detected at E13, the time when neurogenesis is at its maximum. It is detected in the dividing neural precursor cells (NPCs) located at the ventricular and subventricular zone (SVZ), where NPCs reside, proliferate, and differentiate to neural cells, preceding their migration to the developing cortical plate (149, 190, 444) . EGFR null mice present strain-independent postnatal neurodegeneration affecting both neurons and astrocytes, resulting in disturbances in cortical layer formation. In addition, defective neural cell migration indicated by ectopic neuron nests was seen in the EGFR null mice (503, 559) . Conversely, EGF injection induces subependymal neural cells to migrate from the lateral ventricle into the adjacent neural tissue (109) . In embryonic mouse cortical NPCs, tropomyosin receptor kinase B (TrkB), a high-affinity catalytic receptor for several neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin 3 (NT-3), is transactivated by EGF/EGFR signaling to regulate migration of early neuronal cells to their final position in the developing cortex (444) . Therefore, EGFR may play a role in CNS development by promoting the proliferation and survival of both neurons and glial cells and guiding the proper migration of neurons (444, 503, 559) .
EGFR in bone development
EGFR signaling may affect bone formation through regulating endochondral ossification. EGFR null mice show an enlarged hypertrophic chondrocyte zone in the growth plate and delayed primary endochondral ossification (546, 577) . Although EGFR is expressed in chondrocytes and osteoclasts, EGFR inactivation does not alter chondrocyte proliferation, differentiation, or vascular invasion into the hypertrophic cartilage. However, osteoclast formation and recruitment to the chondro-osseous junction (COJ) is reduced due to decreased expression in the growth plate of RANKL [receptor activator of nuclear factor (NF)-B (RANK) ligand], a major determinant for osteoclastogenesis. Meanwhile, EGFR inactivation also decreases expression levels of matrix metalloproteinases (MMP9, 13, and 14), accompanied by increases in collagen fibrils and reduced degradation of extracellular matrix products in the growth plate (639) . Therefore, EGFR signaling may play an essential role in the remodeling of growth plate cartilage extracellular matrix into bone during endochondral ossification.
EGFR and epithelial development
EGFR is an important regulator of epidermal development. EGFR is most abundantly expressed in the basal layer of the epidermis and in the outer root sheath of the hair follicles, the site of proliferating cells (505) . Waved hair due to severe derangements of hair follicles is seen in EGFR-mutation (wa2) and EGFR ligand TGF-␣-mutation (wa1) mice (160, 318) . Similarly, EGFR null mice exhibit strain-dependent defects in epidermal and in hair follicle differentiation and fail to develop normal fur, further indicating an essential role for EGFR signaling for maintenance of hair follicle integrity (207, 318, 355, 505, 546) . EGFR null mice also exhibit eyelid malformations and defects in other epitheliallining organs, such as tongue, colon, and kidney. In the kidney, the collecting duct shows progressive cystic dilation with flattened epithelial lining, whereas no obvious abnormalities are found in other segments (546).
EGFR and kidney development
Kidney development occurs through reciprocal interactions between the ureteric bud (UB) and the adjacent metanephric mesenchyme. The UB branches to form the collecting system of the kidney, whereas the proximal parts of the nephron develop from metanephric mesenchyme (269) . EGF family members are crucial for kidney development. TGF-␣ is expressed in metanephroi (188, 467) . EGFR acts cooperatively with the HGF receptor, cMET, to determine the final nephron number and maintain collecting duct morphology (238). Global EGFR knockout mice have impaired epithelial development in several organs, including the kidney collecting duct, and die at midgestation or shortly after birth (546) . Specific deletion of EGFR in collecting ducts results in a thin renal medulla, with polyuria and impaired urine-concentrating ability, suggesting that EGFR may promote elongation of the emerging collecting ducts, which optimizes urine-concentrating ability (90, 640). In contrast, administration of exogenous EGF to rat pups delays development of the loop of Henle in the inner medulla by reducing both apoptosis and cell proliferation (289).
EGFR and liver development
EGFR signaling is dispensable for hepatic organogenesis as indicated by the normal liver development in EGFR null and wa2 mice, although EGFR, along with ErbB2 and ErbB3, are expressed in the liver parenchyma by E19 (78, 318, 546) .
III. ROLE OF EGFR IN THE SKIN
Human skin expresses EGFR, ErbB2, and ErbB4, but EGFR signaling appears to be most important in skin growth, maintenance, and repair (526) . EGFR is expressed throughout the whole epidermis of normal skin, particularly in the basal cell layer (337) . The EGFR ligands, TGF-␣, AREG, HB-EGF, and EPR, are expressed in human keratinocytes (101, 105, 213, 500) . Under unstimulated conditions, cultured keratinocytes primarily express AREG, with low levels of expression of TGF-␣, HB-EGF, and EPR (500).
A. EGFR Activation and Skin Homeostasis
Under physiological or pathophysiological conditions, EGFR can be activated directly by its ligands or transactivated by a variety of GPCRs, integrins, and cytokine receptors. As an example, during wound healing, angiotensin II activates AT1 receptors, leading to metalloproteinase-mediated shedding of HB-EGF from its membrane precursor, activation of the EGFR/ERK axis, and subsequent keratinocyte and fibroblast migration (614) . Therefore, antagonism of the AT1 receptor, EGFR or ERK can effectively inhibit angiotensin II-mediated wound healing. Integrin-dependent adhesion triggers ligand-independent EGFR activation to transduce downstream signaling at the adhesive site (68) . In addition, protein-tyrosine phosphatases (PTP) limit EGFR functions through dephosphorylation of EGFR (613) . Of note, oxidative stress-mediated inhibition of PTP activity contributes to EGFR activation by UV irradiation (FIGURE 5) (613) .
The EGFR signaling pathway may regulate skin homeostasis through multiple mechanisms that mediate anti-apoptotic and pro-survival pathways. The activation of an EGFR-PI3K-AKT pathway is essential for the anti-apoptotic response of keratinocytes in response to ultraviolet B (UVB) radiation (FIGURE 5) (430) . UV light inhibits the phosphatase activity, leading to activation of RTKs like EGFR (268) . This pathway is also a crucial mediator of keratinocytes' response to oxidative stress (451) . The activation of an EGFR-ERK axis is of particular importance in skin wound healing (333) . AREG, a natural regulator of keratinocyte growth, plays an essential role in the proliferation of cultured human keratinocytes by activation of EGFR via both autocrine and paracrine mechanisms (433) . Of note, overexpression of AREG in basal or suprabasal epidermis leads to psoriasis-like pathology and inflammation, in association with keratinocyte proliferation (104) . Treatment of normal human skin with all-trans-retinoic acids induces both AREG and HB-EGF, and monoclonal antibodies (mAbs) against these ligands attenuate rentinoid acid-induced epidermal hyperplasia in vitro (464) . Integrins trigger multiple signaling pathways and are involved in cell migration, maintenance of cell shape, proliferation, and survival. Integrin-dependent adhesion initiates ligand-independent EGFR activation. In addition, integrin-mediated signaling seems to be necessary for full EGFR-dependent responses (68) . However, EGFR-induced disruption of ␣6␤4 integrin at hemidesmosomes and their disassembly is necessary for normal keratinocyte migration (334).
B. EGFR and EGFR Ligands in Skin Wound Healing
In skin wound healing, keratinocytes play a key role not only because they provide essential structure for skin but also because they are sources of growth factors, including EGFR ligands. EGFR activation is essential in cell proliferation and migration in skin wound healing (FIGURE 5). In wound healing, collagenase-1 (matrix metalloproteinase-1) activity is required for keratinocyte migration on a type I collagen matrix, and autocrine EGFR activation is a required intermediate step to sustain collagenase-1 production (434) .
Shedding of EGFR ligands is required for keratinocyte migration in cutaneous wound healing, and inhibition of this process by metalloproteinase inhibitors suppresses keratinocyte migration (548) . HB-EGF and TGF-␣ are two major EGFR ligands that are upregulated during wound healing, and TGF-␣ has been shown to play a key role in promoting keratinocyte migration during active wound healing (297) . Inhibition of EGFR ligand shedding or EGFR tyrosine kinase activity impairs skin wound healing and is accompanied by marked increases in immune cell infiltration, particularly neutrophils, possibly due to an altered chemokine profile in epidermal keratinocytes (455, 499, 549) . ADAM17 cleaves membrane proteins, such as EGFR ligands, thus regulating responses to tissue injury and inflammation. Selective deletion of either EGFR or ADAM17 in keratinocytes leads to development of marked defects in epidermal barrier integrity and chronic dermatitis, in association with increased cytokine/chemokine levels and increased neutrophil and inflammatory macrophage infiltration (163) .
Recently, it has been reported that interleukin (IL)-33 has a tissue-protective role at the barrier surfaces of skin, as well as lung and intestine. IL-33 can transactivate EGFR through induction of AREG (370 
D. EGFR Inhibition and Skin Adverse Effects
As EGFR is expressed throughout the whole epidermis; contributes to epidermal proliferation, differentiation, and hair growth; and plays key roles in the innate immune responses as well, inhibition of EGFR signaling will inevitably compromise skin integrity (146). Many genetic animal models with increases or decreases in EGFR ligands or EGFR have abnormal skin phenotypes (318) . Wa1 mice, with an autosomal recessive, spontaneous mutation that results in a gradual postnatal reduction in TGF-␣ production, develop curly whiskers and waved coat at a young age. Wa2 mice, with a point mutation in EGFR receptor tyrosine kinase with Ͼ80 -95% reduction of its tyrosine kinase activity, have shorter and bent vibrissae and wavy texture of the pelage. Deletion of EGFR or ADAM17 in keratinocytes leads to chronic dermatitis (163) . Epiregulin-deficient mice develop chronic, epidermal cell-dependent dermatitis in association with increased cytokine IL-18 production in keratinocytes (501) . Transgenic mice with elevated expression of AREG in the skin develop severe psoriasislike hyperplasia and skin inflammation (104, 106) . In the epidermis, EGFR is strongly expressed in the basal keratinocyte layer and in the outer root sheath of hair follicles. Accordingly, mice with an EGFR-dominant negative mutation have curled whiskers and short hair that becomes progressively sparse (378) . However, overexpression of TGF-␣ in epidermis induces minimal skin inflammation (130) . Therefore, the effect of EGFR activation via its individual ligands on skin inflammation is extremely complicated.
Chronic pharmacological EGFR inhibition leads to focal keratinocyte necrosis, which in turn activates and sustains immune cell recruitment and activation, leading eventually to folliculitis (296) . In addition, pharmacological inhibition of an EGFR-ERK signaling pathway worsens skin inflammation. Inhibition of the EGFR-ERK signaling pathway increases chemokine expression in keratinocytes as a result of dramatic stabilization of the related transcripts (419) . Furthermore, antagonism of the EGFR-ERK axis improves the function of the professional antigen-presenting cells of the skin, as indicated by increased expression of cell membrane costimulatory molecules, IL-1␤, CCL/MIP1␣, and CCL17/TARC in mouse Langerhans cells (166). In addition, EGFR inhibition can increase the expression of proinflammatory molecules, including Mig, CX3CL1/fractalkine, and CXCL18/MIP4 (607) . Therefore, targeting EGFR should not be considered an attractive therapy in skin inflammatory disorders associated with epithelial hyperproliferation. Patients with EGFR inhibitor treatment often have altered hair growth, which usually happens within a few months after initiating therapy. These changes include trichomegaly, long curly eyelashes, increased facial hair, dry and brittle scalp hair, and frontal alopecia (511).
E. EGFR Inhibition and Skin Side Effects

IV. ROLE OF EGFR IN THE CENTRAL NERVOUS SYSTEM
As noted above, EGFR is highly expressed in the neural stem cells (NSC) or NPC of the SVZ or SVZ niches in the adult brain (1, 10, 172, 444) . Lower levels of EGFR expression are detectable in certain differentiated neurons in the adult (1, 240) . In addition, a number of neural cell types express EGFR during embryonic and perinatal expression, notably astrocytes, but have low or absent expression in normal adult brain and a reappearance of expression in response to injury (1, 306, 503, 605) .
A. EGFR Expression and Physiological Function in the CNS
In concert with other signaling pathways, such as the Notch pathway, EGFR signaling promotes NSC/NPC proliferation and migration and plays fundamental roles not only in development but also in repair after injury (10, 444) . Different levels of EGFR are also expressed in various types of neurons and/or glial cells in the adult CNS, including midbrain, cerebral cortex, hippocampus, ependymal cells, hypothalamus, pituitary gland, cerebella, dorsal root ganglia, and spinal cord (1, 2, 598) . Therefore, EGFR may play different roles depending on the cell type and its location (TABLE 3) .
In the midbrain, EGFR along with ErbB4 are expressed in the substantia nigra dopaminergic neurons, where EGFR activation contributes to the survival and postnatal development of those neurons (1, 79, 241, 243, 385) . A dopamine-EGFR signaling loop exists in the nigra striatum pathway, and EGF can be produced and released from striatal neurons that express D1-like receptors (D1R) or surrounding glial cells with D2-like receptors (D2R) in a dopaminedependent manner through dopamine binding to D1R or D2R, activating MMPs or ADAMs and cleavage/release of soluble EGF into the synaptic cleft. Soluble EGF binds and activates EGFR in the dopaminergic neuron axon terminals, which then serves as retrograde neurotrophic signals on substantia nigra dopaminergic neurons (242).
GABAergic neurons, such as pyramidal and Purkinje cells, also express EGFR. GABA, a major inhibitory neurotransmitter in the CNS, is synthesized from glutamate, a principal excitatory neurotransmitter, through a GABA shunt. In contrast to its neurotrophic action on dopaminergic neurons, EGFR activation negatively regulates GABAergic neurons' function by attenuating the activity of glutamate receptor channels (2, 380, 384) . EGFR is also expressed in neurons located at the subparaventricular zone (SPZ) of the hypothalamus, the major target field of the suprachiasmatic nucleus (SCN), site of the circadian clock. Activation of EGFR in those neurons by its ligands, in particular TGF-␣, may regulate the circadian clock. TGF-␣ is expressed rhythmically in the SCN and acts as a locomotor inhibitory factor (274). In contrast, wa2 mice with hypomorphic EGFR activity exhibit excessive daytime locomotor activities (274, 510, 520).
B. EGFR and CNS Disorders
Abnormal EGFR signaling has been implicated in the etiology and neuropathology of degenerative brain diseases such as Alzheimer's disease and Parkinson's disease and psychiatric disorders like schizophrenia (240).
Alzheimer's disease
Alzheimer's disease (AD), the most common cause of dementia worldwide, is characterized by degeneration of neural cells in the brain, mainly in the cortex and hippocampus, which is accompanied by extracellular aggregation and deposition of amyloid ␤ (A␤) plaques, intracellular neurofibrillary tangles, and inflammation. Recent analysis of genome-wide studies and protein-protein interaction modeling has identified EGFR as a significant AD risk factor (539) . Although the exact mechanisms remain to be elucidated, the involvement of EGFR signaling in AD pathogenesis is indicated by the evidence that EGFR signaling has neuroprotective effects against excitotoxicity and oxidative stress, and EGFR null mice die before P20 with strain-independent neurodegeneration in both neurons and astrocytes (60, 503) .
Presenilin 1 (PS1) is an important functional component of the proteolytic ␥-secretase complex that cleaves ␤-amyloid precursor protein (APP) and also has ␥-secretase-independent functions in cell signaling, intracellular trafficking, and neuronal survival (31). Loss of functional PS1 causes incomplete digestion of APP and increases the production of A␤42 oligomer, a main form constituent of the AD plaque (122) , and mutations in the gene encoding PS1 cause the most aggressive form of early-onset familial AD (FAD). The absence of PS1 results in a dramatic decrease (Ͼ95%) of neuronal EGFR. In addition, EGFR expression is dramatically reduced in the brain of rats with advanced age, another strong risk factor for AD (219). On the other hand, PS1 null mice have absent survival signaling or protection against excitotoxicity in response to EGF administration, but expressing active EGFR can overcome these defects, even in absence of PS1 (60) .
In contrast to the studies suggesting a neuroprotective role for EGFR in AD, there are also indications that it may play a detrimental role. PS1 deletion does not inhibit EGFR expression in either glial or fibroblast cells, which may contribute to scar formation (60, 578) . Increased levels of EGFR expression are found in the periphery of plaques, astrocytes, and cerebrovascular endothelial cells in AD and may contribute to neuroinflammation (46, 155, 528, 567) . Studies by Wang et al. (578) showed that A␤42 could stimulate EGFR activity in the hippocampus, which correlated with the A␤42-induced memory loss. They have proposed that EGFR may be an important factor that mediates A␤42 toxicity, and inhibition of EGFR activation might be an effective way to treat A␤42-induced memory loss (578).
Parkinson's disease
The characteristic motor dysfunction of Parkinson's disease (PD) results from decreased or absent levels of dopamine in the corpus striatum due to the progressive deterioration of dopaminergic neurons in the substantia nigra. Both EGFR and ErbB4 are highly expressed in the substantia nigra dopaminergic neurons, and their depletion has been implicated in the pathogenesis of PD (240). Surviving postnatal EGFR null mice have fewer neurons and shorter extended neurites (243). Similarly, expression levels of both EGFR and EGF are diminished in the postmortem brains of patients with Parkinson's disease. Rats receiving a dopaminergic neurotoxin exhibit decreased EGFR expression and fewer dopaminergic neurons, and administration of EGF ameliorates these deficits (241, 431, 444) . Similarly, administration of the ErbB4 ligand NRG1, which has high bloodbrain permeability, provided protection of dopaminergic neurons in a rat model of PD (75) . In addition, SVZ in PD have fewer EGFR positive cells and decreased activity of the dopamine-EGFR signaling loop, which may contribute to the reduction of NPCs proliferation and dopaminergic neurogenesis (393).
Schizophrenia
Schizophrenia is a complex and multifaceted neuropsychiatric disorder characterized by delusions, hallucinations, passivity, disordered thought process, disorganized behavior, and progressive cognitive deficits (566) . The most common pathological findings include larger ventricles, decreased gray matter, and smaller hippocampi (26). Even though the exact etiology has not been fully elucidated, neuronal developmental defects and presynaptic dopamine hyperfunction have been associated with this disorder, and EGFR signaling alterations have been discovered in both situations (169, 225). EGF administration during rat development causes hyperdopaminergic pathology and results in abnormal behavioral traits resembling schizophrenia in adult animals (168). In addition, chronic exposure of neonates to EGF appears to permanently sensitize to EGFR signaling (366) . In contrast to the elevated expression of EGFR, individuals with schizophrenia may have decreased EGF in the prefrontal cortex (169, 240). Although it is still uncertain whether increased receptor number or decreased ligand concentration has a more dominant role in schizophrenia, abnormal upregulation of EGFR expression is more consistent with the dopaminergic hyperfunction hypothesis of schizophrenia (169). Alternatively, alterations in EGF/EGFR signaling may have spatial and temporal roles in schizophrenia. For example, decreased EGF/EGFR signaling may contribute to disturbances of oligodendrogenesis and demyelination, another pathological finding in schizophrenia (172) . Therefore, further studies on neural cell-specific expression and dysfunction of the EGFR signaling pathway should provide us more information of its role in schizophrenia.
There is a strong genetic association between disruption of NRG1-ErbB4 signaling pathway and the incidence of schizophrenia (38, 63, 240, 426). As noted, NRG1 is highly expressed in the CNS during the embryogenic and early postnatal period, and its expression decreases with age (63). ErbB4 is the main receptor for NRG1 in the CNS, and its expression pattern partially overlaps with that of EGFR in several regions of the brain, including cortex, striatum, cerebellum, and hippocampus. Furthermore, it is coexpressed with EGFR in GABAergic interneurons (1, 161, 176, 240, 620) . The NRG1-ErbB4 signaling pathway may have multiple roles in the CNS, including promoting glial cell survival (8); stimulating oligodendrocyte formation, axon myelination, and dendritogenesis (426, 461) ; inducing the expression of receptors for neurotransmitters like GABA, NMDA, and acetylcholine (311, 408) ; and mediating neuronal migration to cortical and striatum (158, 569) . Studies in mice with deficiency or mutation of either NRG1 or ErbB4 have indicated that disruption of NRG1-ErbB4 signaling may contribute to the development of schizophrenia (30, 32, 95, 186, 348, 395) . In additional to characteristic behavioral changes, these mice had large ventricles and decreased brain volume with hypomyelination, a reduced number of cortical inhibitory GABAergic interneurons, and fewer astrocytes and oligodendrocytes (354, 426) .
C. EGFR and CNS Injury Recovery
The neurotrophic role of EGFR signaling may promote recovery after injury to the CNS through increased NSC/NPC proliferation and differentiation in the VSZ niches and migration toward the injured area to replenish the injured neurons and facilitation of axon regeneration (6, 217, 599) . HB-EGF, EGF, and EGFR expression increase in the SVZ and the areas surrounding the injury (11, 43, 258, 390, 450) , and EGF or TGF-␣ infusion can promote axon regeneration (217, 599), while specific forebrain HB-EGF deletion exacerbates brain injury (407) . Although EGFR tyrosine kinase inhibitors, such as AG1478 and PD168393, promote neurite growth in in vitro axon growth inhibitory screening, these effects may result from indirect and/or offtarget effects of these inhibitors and are likely not related to EGFR inactivation, since administration of EGFR siRNA could not reproduce this effect (43).
Activation and function of EGFR can either affect or be affected by other EGFR-interacting molecules in the CNS, such as mTOR and LINGO-1 (leucine-rich repeat and immunoglobulin domain-containing protein), which is evolutionarily related to LRIG-1 (14, 43 
V. ROLE OF EGFR IN THE VASCULATURE
Vascular smooth muscle cells (VSMCs) express all EGFR/ ErbB family members along with their respective ligands including HB-EGF, EPR, and BTC (328, 359) . Several GPCRs expressed in VSMCs can transactivate the EGFR, including angiotensin II receptors (see below), ␣-adrenergic receptors, endothelin, and protease activated receptors (226, 298, 484) . In pathophysiological vascular remodeling, EGFR has been implicated as a key element preceding end-organ damage in various cardiovascular diseases including hypertension (536) .
ANG II is the major bioactive peptide in the renin angiotensin system. ANG II binds to two types of GPCRs, ANG II type 1 receptor (AT1R) and the type 2 receptors (AT2R). It is well accepted that most of the physiological and pathophysiological functions of ANG II are mediated through the AT1 receptor. In VSMCs, AT1 activation mediates vasoconstriction as well as hypertrophy, hyperplasia, and migration (257) . Like AT1R, endothelin stimulation of G qcoupled ET-1 receptors or norepinephrine stimulation of G q -coupled ␣1-adrenoceptor also stimulates contraction and proliferation of VSMCs (208) . Activation of the AT1R has been identified as a central component of EGFR transactivation within the vasculature, specifically mediating vascular remodeling (218, 369). EGFR transactivation induced by ANG II in VSMCs is dependent on upstream G q /Ca 2ϩ and/or Src signaling and results in downstream kinase activation (ERK, Akt, p38 mitogen-activated protein kinase, p70S6K), with subsequent NADPH oxidase activation, ROS production, and protein synthesis. ANG II-mediated mechanisms of EGFR transactivation require Ca 2ϩ -dependent phospholipase A 2 (cPLA 2 ), arachidonic acid, p38 MAPK, and phospholipase D in cultured VSMCs (295) . However, there are contradictory publications regarding the role of G protein-independent and ␤-arrestindependent mechanisms of EGFR transactivation by ANG II in VSMCs (263, 401) . Ultimately, these signaling mechanisms culminate in VSMC hypertrophy, hyperplasia, and enhanced migration (144, 145, 218, 401, 492, 555) . Tyrosine phosphorylation-dependent ADAM17 activation and HB-EGF shedding are requirements for ANG II-dependent EGFR activation and VSMC hypertrophy (148, 400) (FIGURE 6). Of note, VMSCs from spontaneously hypertensive rats show decreased proliferation and decreased EGFR phosphorylation when treated with an AT1R blocker (298) .
In addition to promoting pathophysiological VSMC remodeling, AT1R signal transduction has also been linked to vascular inflammation (332) . EGFR transactivation mediates proinflammatory actions of AT1R in VSMCs through transcriptional regulation. ANG II-induced IL-6 expression in VSMCs is mediated through stimulation of a cAMPresponsive element in the promoter via CREB. Subsequent analysis has demonstrated the necessity for EGFR transactivation to mediate CREB-dependent transcription in this cascade (233). Hypoxia inducible factor 1 alpha (HIF-1␣) stimulation in VSMC is another mediator of ANG II-induced proinflammatory responses (234, 353). EGFR transactivation is also required for activation of HIF-1␣ by ANG II in VSMCs (282). Sustained endoplasmic reticulum stress has also been implicated in enhanced inflammatory responses via specific unfolded protein responses, including JNK and NFB activation, as well as stimulation of ER stress responsive elements (194, 635) . ANG II-induced ER stress responses are attenuated in VSMCs that are treated with the EGFR inhibitor erlotinib (536) .
Many of the signaling molecules required for AT1R specific EGFR transactivation are localized to lipid rafts and/or caveolae, the cholesterol-rich membrane microdomains that can act as signaling platforms facilitating temporal and spatial localization of signal transduction (563) . Of these signaling molecules, ADAM17 is compartmentalized within caveolae (399) . Overexpression of caveolin-1 (Cav1), the major structural protein of caveolae, prevents ANG II-induced hypertrophy and migration of VSMCs through suppression of HB-EGF shedding, EGFR transactivation, and ERK activation (534) . However, Cav1 silencing is also protective against EGFR transactivation, suggesting a tight regulatory component via Cav1/caveolae may be critical for EGFR transactivation (535) .
Aldosterone has a synergistic relationship with ANG II and AT1R in EGFR transactivation (342, 360) . Interaction between aldosterone and ANG II enhances VSMC migration through tyrosine kinase c-Src-independent ERK1/2 signaling and c-Src-dependent signaling through EGFR and PDGF receptor activation (368) . An ex vivo study using human coronary microarteries further suggested cross-talk between GPR30 and EGFR upon aldosterone and ANG II cotreatment (33). Additionally, high glucose enhances ANG II signal transduction through N-glycosylation of EGFR. Interestingly, the N-glycosylated form of EGFR may be activated by either EGFR or GPCR ligands, whereas the nonglycosylated form is only sensitive to EGFR ligands, which is suggestive of a selective ANG II mechanism underlying diabetic vascular disorders (270) .
EGFR has been implicated in various vascular disorders including hypertension (252, 253) and the development and progression of abdominal aortic aneurysms (523) . Treatment of ANG II-infused mice with erlotinib attenuates vascular hypertrophy and perivascular fibrosis independent of alterations in blood pressure (536) . Furthermore, either pharmacological or genetic EGFR inhibition can inhibit ANG II-induced hypertrophy in cerebral arteries in mice without reducing blood pressure (82) . Recent studies show that EGFR activation leads to inhibition of epithelial sodium channel (ENaC) activity in collecting duct, suggesting that inhibition of EGFR activity under circulatory volume expansion conditions may lead to elevation of blood pressure (432) .
EGFR expression and activity are crucial for the induction of a distinct intratumoral vasculature that facilitates tumor metastasis (361, 485) . EGFR facilitates metastasis through VEGF-mediated disruption of endothelial layer integrity and increase of intratumoral vasculature permeability. Therefore, a combination of EGFR inhibition and anti-VEGF approaches may provide a better chemotherapy in some tumors.
VI. ROLE OF EGFR IN THE HEART
EGFR appears to play a critical role in both normal physiology and pathophysiology of the heart. EGFR inhibition suppresses cardiac hypertrophy, which requires HB-EGF production (69, 518, 536, 633) . Supporting this notion, ADAM12 is responsible for ANG II-induced HB-EGF shedding and downstream EGFR transactivation and cardiac hypertrophy (20) . In addition, cardiac fibroblast proliferation by ANG II, PAR-1, or endothelin is also mediated through EGFR transactivation (84, 470, 493, 574).
However, apart from pathophysiological cardiac remodeling, EGFR has also been implicated in mediating cardiac myocyte survival. Stimulation of ␤ 1 -adrenergic receptors (␤ 1 AR) using dobutamine causes EGFR transactivation and ERK activation in cardiac myocytes. EGFR transactivation requires G protein-coupled receptor kinase-5 and -6 mediated ␤-arrestin recruitment with a subsequent cascade of EGFR transactivation including Src, a metalloprotease, and shedding of HB-EGF (391). Importantly, this mechanism of EGFR activation is protective, as interruption of this cascade leads to myocyte apoptosis in vitro (391) . Additionally, ␤-blockers such as alprenolol and carvedilol, which are known mediators of biased agonism, have been shown to induce EGFR transactivation through a ␤ 1 AR/␤-arrestindependent mechanism (262) . Similarly, mechanical stress elicits AT1R-induced EGFR transactivation through ␤-arrestin-dependent biased agonism, resulting in suppression of apoptosis in cardiac myocytes (448) . Studies to investigate how EGFR can have both beneficial and detrimental effects on the heart have identified both spatial and temporal differences in ERK activation as a result of EGFR transactivation. Rapid and transient ERK1/2 expression and localization to the nucleus involves a G protein-dependent pathway in cardiac remodeling, whereas cytosolic localization and sustained ERK activation is dependent on ␤ 1 ARinduced EGFR transactivation and is antiapoptotic due to activation of 90-kDa ribosomal S6 kinase which has been shown to inhibit BAD-induced apoptosis (547).
Similar to in vitro studies, ␤ 1 AR and ␤-arrestin are critical for EGFR-mediated cardioprotection in animal models. Transgenic mice expressing ␤ 1 AR with a G protein-coupled receptor kinase mutation fail to induce EGFR transactivation and develop left ventricular dilation and cardiac dysfunction when treated with isoproterenol. Similarly, mice cotreated with isoproterenol and erlotinib experience increased myocardial apoptosis, left ventricular dilation, and decreases in cardiac function; gefitinib, another EGFR TKI, prevents cardiac hypertrophy as a result of isoproterenol treatment but stimulates cardiac fibrosis when used alone (193) (FIGURE 7 ).
In addition, NRG1/ErbB signaling has been shown to be critical for cardiac development and maintenance of structural and functional integrity in adult heart (338, 349, 425) . Lifelong expression of NRG1 is located in the endocardial endothelium, where it activates its receptors either in the cardiomyocytes (ErbB2 and ErbB4) or in mesenchymal cells of the endocardial cushion (ErbB3) through paracrine or juxtacrine binding to ErbB4 or ErbB3 (290). Although NRG1 is not able to bind ErbB2 directly, ErbB2 is the preferred partner for ErbB3 and ErbB4 for heterodimerization (192) . During embryonic development, NRG1/ErbB signaling is involved in embryonic stem cell differentiation into cardiac myocyte lineages, sustains the cardiac gene regulatory network in myocardium, and stimulates cardiomyocyte differentiation into cardiac conduction system (280, 396, 454, 586) . The indispensable role of the NRG1/ErbB pathway in cardiac morphogenesis was revealed by NRG1-, ErbB2-, and ErbB4-null mice, all of which die around embryonic day 10.5 lacking ventricular trabeculation (176, 286, 352) . Neither ErbB2 nor ErbB4 alone can compensate for the loss of the other receptor, suggesting ErbB2/ ErbB4 heterodimers are required for NRG1 signaling in the heart (290).
In adults, NRG1/ErbB signaling participates in the maintenance of cardiac structure and function (396) , which was first revealed by an unforeseen cardiotoxicity of Trastuzumab, a monoclonal antibody against ErbB2, used in the treatment of breast cancer (151, 515) . Similarly, conditional inactivation of ErbB2 or ErbB4 in ventricular myocytes causes dilated cardiomyopathy (110, 175) . NRG1/ ErbB signaling also mediates cardiac adaptations to stress in physiological conditions during exercise or pregnancy, and in pathological situations during cardiac infarction, high cardiac overload, or heart failure through activation of intracellular kinase cascades that regulate tissue plasticity (396) . In vitro studies on cardiomyocytes showed that NRG1/ErbB signal activation initiates downstream pathways that include ERK1/2 and PI3-kinase/Akt. The hypertrophic response to NRG1 relies mainly on ERK1/2 activation, whereas the antiapoptotic effects are more likely to be Akt dependent (290, 396) . In addition, ErbB2-dependent activation of focal adhesion kinase (FAK) has been associated with restoration of cell-to-cell contact between isolated cardiomyocytes (276). More recently, several studies reported that activation of NRG1/ErbB2 pathway promotes heart regeneration in zebrafish and prolongs the ability of the newborn mouse heart to regenerate in the first few days after birth (111, 180, 438) . As for heart failure, increased expression levels and activation of NRG1/ErbB signals have been detected in the early stage of cardiac injury compensated heart failure or other myocardial stress conditions, and these elevations decreased with disease progression and decompensation (290, 349) . Administration of NRG1 ameliorates cardiac dysfunction and reduces the mortality of left ventricular (LV) failure in models of ischemic, dilated, and viral cardiomyopathy and also exhibits direct anti-remodeling effects on the pressure-overloaded right ventricle (RV) in a rat model (310, 349) . These findings have pinpointed NRG1/ErbB signaling activation as a therapeutic target for heart failure, and phase II clinical trials so far have showed efficacy and safety of NRG1 in improving LV function in patients with heart failure (NCT01251406, www. ClinicalTrials.gov) (174) .
VII. ROLE OF EGFR IN THE LUNGS
EGFR plays an important role in regulation of lung development, maturation, normal respiratory function maintenance, and tumorigenesis, and abnormalities in the EGFR signaling pathway have been linked to a number of respiratory diseases.
There are two types of pneumocytes lining the alveoli of the lungs: type I pneumocytes and type II pneumocytes. Type I pneumocytes are squamous and cover ϳ90 -95% of the alveolar surface, whereas type II pneumocytes cover a small fraction of the alveolar surface area. Type I cells are involved in the process of gas exchange between the alveoli and blood, and type II pneumocytes secrete pulmonary surfactant, which decreases the surface tension within the alveoli (150) . Both EGF and EGFR are expressed in primary cultured type II pneumocytes (446, 587) . Other members of the EGFR family, including HER2, HER3, and HER4 and their ligands, such as TGF-␣, HB-EGF, epiregulin, and neuregulins, are expressed in type I pneumocytes and are involved in lung development and damage repair by promoting cell growth and differentiation (156) . As noted above, inhibition of EGFR activation in pregnant rats induces atelectatic lungs with reduced amounts of surfactant protein-A in surviving pups (183, 284, 447, 544) . Similarly, delivery of an antisense EGF oligodeoxynucleotide or antimouse EGF antiserum to pregnant mice causes defects in type II epithelial cell development and reduced branching morphogenesis in embryonic lung (291, 435, 494, 587) . Mucus secreted by airway epithelial cells and the infiltration of neutrophils into airway lumen are important for maintaining patent airways (382) . In normal individuals, mucus is secreted to coat the airway, prevent water loss, and trap inhaled material, which is then removed by mucociliary clearance. Although acute mucus secretion is an effective airway defense, pathological mucus hypersecretion and poor mucus clearance can lead to airway obstruction. Normal mucus is a mixture of mucin glycoproteins, electrolytes, water, and secreted lipids and peptides stored in a highly compacted state in cytoplasmic granules of airway goblet cells and submucosal glands (299) . MUC5AC mucin is a major component of airway mucus, and EGFR activation modulates its expression in response to reactive oxygen species (495) . Mucin-producing goblet cell production and secretion of mucin increase with EGFR activation (65, 468, 538) .
Acute lung injury (ALI) is a complex inflammatory syndrome with an annual incidence of ϳ200,000 in the United States and a high mortality rate (156) . ALI results in damage to the alveolar capillary barrier leading to airspace flooding with protein-rich fluid and manifests as pulmonary edema in the absence of left ventricular dysfunction. Airway epithelial cell injury resulting in loss of cell-cell adhesion and increased paracellular permeability is central to the pathogenesis of ALI, and efficient repair of the alveolar epithelium is critical to the restoration of lung function and prevention of fibrosis in the setting of ALI (156) . Recovery of ALI is marked by early alveolar type II pneumocyte proliferation and migration followed by differentiation into alveolar type I pneumocyte cells (156) . EGFR ligands play critical roles in lung repair, including alveolar epithelial cell-cell adhesion, migration, growth, and differentiation (96, 156, 178, 179, 251). Expression of the metalloproteinases, MMP-9 and MMP-2, induced by EGFR-dependent activation of ERK1/2 and PI3K/Akt signaling cascades are also important for promotion of airway epithelial cell migration and wound repair in response to airway epithelial cell injury (7).
Expression of EGFR is also upregulated in a number of chronic airway diseases such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis and is associated with mucous hypersecretion and inflammatory cell infiltration (64, 382) . Expression of both EGF and EGFR markedly increases in asthmatic airways (13) and has been shown to provide protection against epithelial injury by stimulating mucin production and inflammatory cell recruitment to the site of injury to initiate repair (64) . However, other studies suggest that amphiregulin-dependent activation of EGFR can mediate development of pulmonary fibrosis through activation of fibroblast proliferation (260, 580, 642) , that overexpression TGF-␤ correlates with development of idiopathic or bleomycin-induced pulmonary fibrosis (271, 325, 326, 336) , and that EGFR inhibitors reduce pulmonary fibrosis (209, 239, 562) . Local release of AREG by human mast cells plays an important role in lung fibrosis by promoting the proliferation of primary human lung fibroblasts. In bleomycin-induced pneumopathy in mice, intrinsic expression of AREG increased, and treatment with recombinant human AREG improved the survival rate and suppressed inflammation and fibrosis. AREG also reduces the development of pulmonary fibrosis associated with TGF-␤ activation in idiopathic pulmonary fibrotic mouse model (167, 580, 642) . In addition, EGFR activates Na ϩ resorption across alveolar epithelial cell monolayers via upregulation of Na ϩ pump subunit mRNA expression and protein synthesis, leading to increased numbers of functional Na ϩ pumps in the basolateral membranes, suggesting a possible role for EGFR in enhancing alveolar fluid clearance in the setting of congestive heart failure and other diseases characterized by alveolar edema (119).
VIII. ROLE OF EGFR IN THE KIDNEY
A. EGFR in Renal Physiology
EGFR activation in the kidney occurs through both liganddependent and -independent pathways and is implicated in kidney development, physiology, and pathophysiology. Different EGFR ligands, such as EGF, HB-EGF, TGF-␣, (288, 381, 631 (476) . However, other EGF family members are expressed in other segments; for example, HB-EGF is expressed in the ureteric bud as early as E14.5 and persists into adulthood in the collecting duct, which arises from the ureteric bud (224, 474), and AREG is expressed in developing glomeruli (288, 381) . Expression of EGFR is highest in proximal tubules, followed by cortical collecting ducts, inner medullary collecting ducts, outer medullary collecting ducts, and DCT in adult kidney (59, 565, 632) . Intrarenal infusion of EGF reduces GFR by both preglomerular and postglomerular arteriole constriction, resulting in a decrease in the ultrafiltration coefficient (212). In tubules, EGF stimulates proximal tubule epithelial cell uptake of organic anions (478, 479) . EGFR transactivation by glucose in proximal tubule epithelial cells upregulates serum glucocorticoid regulated kinase 1 (SGK-1) and subsequent NHE3 expression, thereby enhancing proximal tubular sodium reabsorption (469) . In cortical collecting duct, EGFR activation attenuates Na ϩ reabsorption by direct inhibition of the ENaC (72, 404, 496, 553, 588) . EGFR activation may also antagonize the effect of aldosterone to attenuate Na ϩ reabsorption (196) . Therefore, EGFR activation in the proximal tubule epithelial cells may enhance sodium reabsorption, while activation in distal nephron may reduce sodium reabsorption (FIGURE 8). Moreover, decreases in cortical EGF levels followed by promoting ENaC-mediated Na ϩ reabsorption in the collecting duct was suggested to cause development of hypertension diet in salt-sensitive rats (421) .
Magnesium (Mg 2ϩ ) is an important cofactor for many cellular functions, including DNA synthesis, neurotransmission, kinase activation, and hormone receptor binding (118) . The Mg 2ϩ concentration is regulated within a narrow range in blood, and the kidney plays a key role in Mg gene, that results in missorting of the ligand thereby decreasing renal EGFR activation, inhibiting TRPM6 activity, and increasing urinary magnesium excretion (195) . Thus it is not surprising that patients treated with drugs that block EGFR activity can experience hypomagnesemia (128, 181).
B. Acute Kidney Injury
In many cases, kidneys undergoing AKI caused by either ischemic or renal toxic insults can completely recover function. The current paradigm is that surviving proximal epithelial cells undergo dedifferentiation, proliferation, migration, and ultimately redifferentiation into mature tubular cells, regulated by different growth factors (52, 135). Administration of exogenous EGF enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in ischemia reperfusion-induced AKI (232), mercury chloride nephrotoxicity (102) , and gentamicin nephrotoxicity (372) . Although renal pro-EGF mRNA and EGF excretion decrease in both cisplatin and ischemia reperfusion-induced AKI (441, 472) , other EGFR ligands, such as HB-EGF and epiregulin, are upregulated in AKI models and may mediate renal epithelial cell proliferation (224, 474, 645, 646) . In addition, EGFR expression (471) and EGFR activation increase in response to AKI (201) . Deletion of EGFR in proximal tubule epithelial cells or administration of the EGFR tyrosine kinase inhibitor erlotinib significantly delay kidney functional and structural recovery from ischemia reperfusion-induced AKI (87). Similarly, genetic (wa2 mice) or pharmacological EGFR inhibition leads to more severe renal dysfunction, histologic damage, and tubular cell apoptosis after toxin-induced AKI (214, 585).
C. Chronic Kidney Injury
Although regulated EGFR activation in response to acute tubule injury is important for effective epithelial cell regeneration, persistent and dysregulated renal EGFR activation can lead to progressive fibrosis. In cell culture, soluble HB-EGF or EGFR transactivation by ANG II induces dedifferentiation of inner medullary collecting duct cells or proximal tubule epithelial cells (86, 90, 517). In vivo, both renal proximal tubule epithelial cell EGFR deletion mice and administration of an EGFR tyrosine kinase inhibitor to mice attenuated ANG II-induced kidney fibrosis (445).
Selective proximal tubule EGFR inhibition reduces tubulointerstitial fibrosis in response to subtotal nephrectomy or prolonged ischemia reperfusion-induced AKI (542) . Severe ischemia reperfusion-induced AKI induces sustained EGFR activation, resulting in activation/proliferation of renal interstitial myofibroblasts and development of renal fibrosis (540) , and pharmacological inhibition of EGFR inhibits macrophage accumulation and interstitial alpha-smooth muscle actin (␣-SMA), a marker of fibrosis. Similarly, mice with global deletion of HB-EGF have less morphological damage after severe ischemia reperfusion-induced AKI (374) . Inhibition of EGFR tyrosine kinase with erlotinib also prevents cisplatin-induced nephrotoxicity in rats (572).
Diabetic nephropathy
Diabetic nephropathy (DN) is a common complication in patients with diabetes mellitus and is characterized by glomerulosclerosis and tubulointerstitial fibrosis and ultimate progression to end-stage renal disease. Kidney enlargement (hypertrophy) is an early manifestation of poorly controlled diabetes, and inhibition of EGFR expression or activity attenuates the hypertrophy (9, 181, 592). TGF-␤ has been implicated in the development of the progressive glomerular and tubular injury in DN, and EGFR activation can mediate the increased TGF-␤ expression and signaling (88, 90, 91, 564, 608, 609). Another proposed mediator of diabetic kidney injury is advanced glycation end-products (AGEs), which result from nonenzymatic protein glycosylation. The detrimental effects of AGEs have been attributed to several AGEbinding proteins, including the receptor for AGE (RAGE), as well as other AGE receptors (AGER) (70) . ERK1/2 activation in mesangial cells, epithelial cells, and renal fibroblasts occurs through a RAGE/ROS/EGFR-dependent pathway (93). Conversely, overexpression of AGER1 will sequester EGFR and inhibit MAPK activation and thus mitigate the toxicity of AGEs (70) . Of note, our recent study indicated that crosstalk between activation of EGFR and Hippo signaling pathway in diabetic renal proximal tubule epithelial cells may contribute to development or progression of DN (92).
Increased endoplasmic reticulum (ER) stress has been linked to the development of diabetic nephropathy (322) , and impaired autophagy is also implicated in development of DN (266) . EGFR inhibition slows progression of experimental DN in association with a decrease in ER stress and an increase in autophagy (636) . Furthermore, administration of EGFR tyrosine kinase inhibitors or selective EGFR deletion in podocytes significantly attenuates diabetic nephropathy development and progression (88).
Polycystic kidney disease
Polycystic kidney disease (PKD) is inherited as autosomal recessive (ARPKD) or autosomal dominant (ADPKD) traits (420) , and EGFR activation has been implicated in cyst development and/or growth. EGF can stimulate cystic epithelial proliferation in both ADPKD and ARPKD (132, 604) . Levels of EGFR ligands are increased in cyst fluid (324) . Furthermore, EGFR is mislocalized to the apical surface of cyst lining epithelial cells (641) . Transgenic mice overexpressing TGF-␣ develop renal enlargement, glomerular mesangial expansion, and renal cyst formation (317) . Expression of amphiregulin and HB-EGF are upregulated and activate EGFR in an ARPKD mouse model (324) . In ARPKD models, in which the cysts are predominantly in collecting ducts, EGF deficiency may contribute to cyst growth, which may be related to EGFR-mediated inhibition of collecting duct ENaC activity (177, 460) . In contrast, in models of ADPKD, in which cysts develop all along the nephron, administration of EGFR tyrosine kinase inhibitors attenuates cyst growth (554).
Although EGFR activation has only minimal influence on systolic blood pressure under physiological conditions (485) , activation of EGFR in kidney may contribute to development of kidney injury resulting from hypertension. Overactivation of an EGFR-ERK pathway in response to oxidative stress and c-Src-dependent transactivation of EGFR contribute to leptin-induced hypertension (248). In the kidneys of deoxycorticosterone acetate salt-induced hypertensive rats, EGFR expression is upregulated, especially in the media of afferent and efferent arterioles (37, 621).
Moreover, administration of EGFR tyrosine kinase inhibitors to a rat model of hypertension prevented the decline of renal function and the development of renal vascular and glomerular fibrosis (162).
There is also EGFR activation in nonhypertensive models of renal injury, including unilateral ureteral obstruction and calcineurin inhibitor-induced fibrosis, with genetic or pharmacological EGFR inhibition decreasing the extent of the tubulointerstitial fibrosis (307, 463) . Similarly, EGFR is activated in a model of hyperuricemic nephropathy with severe glomerular sclerosis and renal interstitial fibrosis, and injury can be prevented by an EGFR inhibitor (308) . Upregulation of expression of HB-EGF in podocytes has been implicated in the development of glomerulopathy induced by puromycin aminonucleoside (PAN) in rats (412, 413) , and induction of HB-EGF and subsequent EGFR activation in the glomerulus mediates injury in an experimental model of rapidly progressive glomerulonephritis (RPGN) induced by anti-GBM serum (50, 153). In addition, upregulation of HB-EGF in mesangial cells is involved in mesangial proliferation in glomerulonephritis (437, 537) .
IX. ROLE OF EGFR IN THE GASTROINTESTINAL SYSTEM
A. EGFR and GI Tract Homeostasis
EGF is expressed in salivary glands, duodenal Brunner's glands, and Paneth cells of the small intestine and pancreas, but not in the gastrointestinal mucosa (34, 440). EGFR is expressed in all epithelial tissues along the human gastrointestinal (GI) tract (54), and global EGFR deletion leads to profound intestinal epithelial defects in newborn mice (546) . EGFR ligands are also expressed in all epithelial tissues along the human GI tract (54, 164). Growth of intestinal epithelium in organ culture is dependent on EGFR signaling (4). Enterocytes of the intestinal epithelium are continually regenerated. They arise from precursor cells in crypts, migrate along villi, and finally die 3-4 days later through anoikis, a form of apoptosis induced by cell detachment, when they reach the villus apex. EGFR is involved in enterocyte anoikis through the dismantling of E-cadherinmediated junctions (320) . The G protein-coupled peptide YY neuropeptide receptor YY1 subtype is highly expressed in the proliferative zone of human colonic crypt epithelial cells, and its activation stimulates proliferation of gut epithelial cells via EGFR (330) . Glucagon-like peptide-2 is secreted by enteroendocrine cells in response to nutrient ingestion and can induce the expression of EGFR ligands including AREG, EPR, and HB-EGF, in association with crypt cell proliferation and bowel growth in vivo (628) . Ghrelin produced in the GI tract is known to stimulate the proliferation of intestinal epithelial cells and other cell types, and EGFR transactivation contributes to ghrelin-mediated intestinal epithelial cell proliferation (591) . In Drosophila, multiple EGFR ligands are induced in response to damage or stress that activate EGFR in intestinal stem cells, leading to their division and midgut epithelium regeneration, thereby maintaining tissue homeostasis (62, 249).
B. EGFR and GI Tract Function
Enterocytes, or intestinal absorptive cells, are responsible for uptake of ions, water, and other substances. EGFR signaling inhibits chloride secretion across intestinal epithelial cells. Growth hormone also inhibits chloride secretion in human colonic epithelial cells through EGFR transactivation (99) . Muscarinic agonists induce EGFR transactivation through metalloproteinase-dependent extracellular release of TGF-␣ and intracellular Src activation, which in turn counteracts carbachol-stimulated chloride secretion across intestinal epithelial cells (343) . EGF-mediated inhibition of intestinal epithelial chloride secretion is regulated by protein tyrosine phosphatase nonreceptor type 2 (480). Cholinergic agonists transactivate EGFR, leading to goblet cell secretion (256) . EGFR transactivation also contributes to lysophosphatidic acid-induced acute stimulation of Na ϩ and fluid absorption in human intestinal epithelial cells and mouse intestine via the Na ϩ /H ϩ exchanger 3 (NHE3) (624) . Secretion of gastric mucus phospholipids in response to ␤-adrenergic G protein-coupled receptor activation is also mediated by SRC kinase-dependent EGFR transactivation (516) . Gastric acid secretion is mediated by H ϩ -K ϩ -ATPase, and EGFR activation promotes H ϩ -K ϩ -ATPase ␣-subunit expression, thereby activating gastric acid production (519, 525).
EGFR in GI tract injury
EGFR and its ligands are induced after GI injury and play an important role in mucosal repair and promote intestinal epithelial cell growth (152) , survival (164, 616) , and restitution (164) . Increased TGF-␣, HB-EGF, and AREG expression and EGFR activation promote gastric mucosa cell migration and proliferation to restore its integrity in response to acute gastric injury induced by administration of either acidified taurocholate or HCl, hypertonic saline, oxidative stress, or osmotic stress (365, 439, 453) . Acute gastrointestinal radiation syndrome (AGRS) is a life-threatening situation that develops after high-dose whole body exposure to ionizing radiation. Recent animal studies suggested that administration of recombinant human EGF significantly improved recovery of small intestinal mucosa from irradiation-induced mucosal damage by suppression of cell apoptosis, stimulation of cell proliferation, and crypt regeneration (287, 397, 422) . EGFR signaling is also essential for the adaptive response of the remnant intestine to massive small bowel resection (392).
Inflammatory bowel disease
Impaired EGFR signaling occurs and may be causal in multiple intestinal inflammatory conditions (164, 402) . Mice with EGFR or TGF-␣ deletions are more sensitive to experimental colitis, while mice with overexpression of TGF-␣ or with EGF administration are relatively resistant (134, 142, 143, 442) . In addition, EGFR transactivation underlies protection by a number of other agonists (57, 164, 344, 618) . For example, in an animal model of dextran sulfate sodium (DSS)-induced colitis, TLR-mediated signals induce EGFR transactivation due to ADAM17-mediated AREG release, leading to protection against DSS-induced colitis (57, 379). p40, a probiotic bacteria-derived soluble protein, reduces intestinal epithelial apoptosis and disruption of barrier function in the colon epithelium in an EGFR-dependent manner, preventing and treating DSS-induced intestinal injury and acute colitis. EGFR activation by p40 is also required for ameliorating colon epithelial cell apoptosis and chronic inflammation in oxazolone-induced colitis (618) . EGF can also improve transepithelial cell ion transport (344) . Of note, AREG/EGFR signaling enhances regulatory T-cell suppressive function (629) . In humans, EGF has been reported to be beneficial in a double-blinded clinical trial with ulcerative colitis (514) . Although the intestine of unchallenged homozygous ADAM17
(ex/ex) mice was normal, ADAM17
(ex/ex) mice showed substantially increased susceptibility to inflammation in DSS colitis (81) . Furthermore, patients with loss-of-function mutation in ADAM17 develop inflammatory skin and bowel disease (48).
Necrotizing enterocolitis
EGF in human milk is protective against NEC, and premature infants with NEC have decreased serum and intestinal EGF (589) . Loss of EGF/EGFR signaling is associated with NEC development, and EGF administration is beneficial in severe NEC (137, 532). HB-EGF also protects intestinal stem cells from injury in a rat model of necrotizing enterocolitis (85). HB-EGF administration reduces experimental NEC severity, barrier defects, and incidence, in association with decreases in epithelial apoptosis and increases in epithelial proliferation and migration (152) .
C. EGFR in GI Tumorigenesis
Both EGFR and its ligands have been implicated in tumor development along the entire GI tract, and their expression is an indicator of poor prognosis (29, 54, 170, 351, 576, 622) . ADAM17-deficient mice have increased susceptibility to increased gastrointestinal injury (81), but ADAM17 expression is increased in gastrointestinal stromal tumor (GIST) tissue in association with EGFR activation, suggesting that ADAM17 may contribute to the progression and growth of GIST through shedding of EGFR ligands and consequent EGFR stimulation. In addition, TGF-␤-activated ADAM17 release of soluble HB-EGF and subsequent EGFR transactivation are implicated in gastric cancer cell proliferation (140). ADAM17 is also overexpressed in primary and metastatic colorectal cancer (CRC) (350) . Activation of a TGF-␣/EGFR axis contributes to azoxymethane-induced colonic tumorigenesis (329) . Human intestinal serrated polyps are a heterogeneous group of benign lesions, but some progress to colorectal cancer. EGFR phosphorylation increases in human hyperplastic polyps, sessile serrated adenomas, and traditional serrated adenomas, and transgenic mice with intestinal HB-EGF overexpression develop serrated polyps (51). Overexpression of BTC stimulates growth of the mouse intestinal epithelium, increases adenoma multiplicity in Apc ϩ/Min mice, and leads to hyperplastic gastric lesions (116, 117) . EphrinA5 is a putative tumor suppressor. In colon cancer cell line models, ephrinA5 exerts an inhibitory effect on EGFR by promoting c-Cbl-mediated EGFR ubiquitination and degradation (581) . Cyclooxygenase-2 (COX-2)-derived prostaglandin E 2 (PGE 2 ) has growth-promoting actions on GI mucosa as well as protumorigenic effects in the GI tract (637) . PGE 2 transactivates EGFR and triggers a mitogenic signaling pathway in normal gastric epithelial and in colon cancer cell lines (410) . In intestinal adenoma Apc ϩ/min mice, COX-2 expression and EGFR activation are simultaneously increased in the intestinal enterocytes and adenomas, suggesting possible PGE 2 -mediated EGFR transactivation in vivo (371) .
H. pylori infection induces a chronic inflammatory response and is a risk factor for gastric carcinogenesis. EGFR signaling pathway is activated in gastric epithelial cells during H. pylori exposure due to metalloproteinase-dependent release of HB-EGF (44, 573, 617) . In gastric epithelial cells, H. pylori infection-mediated EGFR transactivation also leads to upregulation of COX-2, which itself has been shown to contribute to the development of GI tumors (141, 220). In addition, H. pylori infection activates gastrin gene expression via activation of an EGFR-Raf-MEK-Erk1/2 signaling pathway to increase gastric acid secretion, which can cause chronic ulcers and progressions to cancer (600) . H. pylori infection also induces EGFR transactivation by either HB-EGF or Src activation to activate Akt, ERK signaling, and Bcl family members, which results in survival of gastric epithelial cells with DNA damage (83) and may cause unrestrained epithelial cell proliferation and carcinogenesis (259, 617 ).
Ménétrier's disease is a rare premalignant disorder of the stomach that has no proven effective medical therapy. Increased EGFR signaling has been implicated in the pathogenesis of Ménétrier's disease. In severe Ménétrier's disease in which gastrectomy was being considered, treatment with cetuximab (mAb against EGFR) for a month led to significant improvement in both quality-of-life indices and increased parietal cell mass and gastric acidity, and continuous treatment resulted in near-complete histological remission in some patients (157) .
Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model (409) . Either a selective COX-2 inhibitor (celecoxib) or a selective EGFR inhibitor (erlotinib) markedly reduced both the number and size of small intestinal adenomas in Apc ϩ/min mice, and combined treatment with both celecoxib and erlotinib almost eliminated adenoma formation (61) . A recent meta-analysis study indicates that a combination of anti-EGFR agents with noncapecitabine chemotherapy or better supportive care might benefit patients with upper GI tract cancers (293) . Cetuximab and Panitumumab have been used to treat EGFRexpressing metastatic CRC with disease progression or refractory EGFR-expressing metastatic CRC in patients with wild type KRAS.
X. ROLE OF EGFR IN THE LIVER
The liver has an extraordinary capacity for regeneration in response to resection or necrotic tissue loss. EGFR plays a key role in liver reparative and regenerative response to liver injury. Hepatocytes express high levels of EGFR (78, 424) , and global EGFR deletion leads to embryonic lethality or death shortly after birth depending on genetic background, in association with abnormalities of liver and other organs (546) . Perinatal deletion of EGFR in hepatocytes results in decreased liver weight. EGFR expression increases in response to partial hepatectomy (25). Partial hepatectomy is the most common model to investigate mechanisms of liver regeneration (24). Deletion of EGFR in hepatocytes in adult mice leads to increased mortality and liver damage, with decreased liver regeneration after partial hepatectomy due to reduced hepatocyte proliferation as a result of defective G 1 -S phase entry (386) . Similarly, RNA interference of hepatic EGFR also causes impaired liver regeneration (415) .
The EGFR ligands AREG, TGF-␣, HB-EGF, and EPR increase in response to liver injury and regeneration. These EGFR ligands increase at different time points after partial hepatectomy. EGF, AREG, and HB-EGF increase early and are important for initiation of liver regeneration, whereas TGF-␣ expression occurs relatively later (41, 265, 346, 376) . AREG expression is not detectable in the normal liver, but it is markedly induced during acute liver injury and acts as a potent pro-regenerative and survival factor. Increased AREG expression is also detected in humans with chronically impaired liver function, such as liver cirrhosis (40). In isolated hepatocytes, AREG is a primary mitogen through activation of the EGFR/AKT and STAT3 survival pathways and upregulation of Bcl-xL. AREG null mice exhibit impaired proliferative responses after partial liver resection (41). HB-EGF is another key EGFR ligand for hepatocyte progression through the G 1 /S transition during liver regeneration after partial hepatectomy (363) . TGF-␣ is the major EGFR ligand that is readily detected in the normal liver, and its delayed increase after partial hepatectomy suggests a trophic/differentiation function for this ligand (595) . In addition, liver ADAM17 expression also increases in response to partial hepatectomy (303) . Protein tyrosine phosphatase 1B (PTP1B) is a key regulator of metabolism and cell growth by its ability to dephosphorylate tyrosine kinase receptors, including EGFR. In PTP1B null mice with partial hepatectomy, liver regeneration is enhanced due to activated EGFR signaling pathways (457) . Dsk5 mice, which have a gain of function in EGFR caused by a point mutation in the kinase domain, have larger hepatocytes with modestly increased hepatocyte proliferation. These mice have more cholesterol and decreased phospholipid and fatty acid in the livers and an elevated total plasma cholesterol resulting mainly from an increase in low-density lipoprotein, suggesting that the EGFR may play a regulatory role in hepatocyte function and lipid metabolism in adult male mice (481) . Moreover, recent studies in a transgenic mouse model expressing a hepatocyte-specific dominant-negative EGFR indicate that liver regeneration is markedly delayed in response to partial hepatectomy by inhibition of both cell proliferation and lipid synthesis (316) .
EGF also contributes to regeneration after liver injury through the EGFR/STAT signaling pathway and protects the liver against both alcohol-induced liver injury and liver sensitization to bacterial lipopolysaccharide through downregulation of apoptosis (123, 583) .
Activation of the hepatic wound healing response to chronic stimuli may lead to liver fibrosis. In the CCl 4 -induced liver fibrosis model, expression levels of ␣-SMA and collagens are markedly reduced in AREG null mice compared with wild-type mice. In addition, AREG null mice also exhibit reduced expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) and CTGF, two pro-fibrotic components. These results indicate that persistent AREG-mediated EGFR activation may contribute to liver fibrosis (428) .
A. EGFR and Liver Tumorigenesis
EGFR plays an essential role in the development of hepatocarcinoma. In addition, a recent study suggested that EGFR is required in liver macrophages to transcriptionally induce interleukin-6, which triggers hepatocyte proliferation and hepatocellular carcinoma (281). Although AREG is not detectable in healthy liver, its expression is detected in chronically injured liver and human hepatocellular carcinoma tissues and cell lines. AREG acts as a mitogenic and antiapoptotic growth factor for hepatocarcinoma cells and contributes to the transformed phenotype. Genetic inhibition of AREG leads to decreases in constitutive EGFR signaling, inhibition of cell proliferation and anchorage-independent growth, and enhanced apoptosis. In contrast, AREG overexpression increases liver cancer cell proliferation, anchorage independent growth, drug resistance, and in vivo tumorigenic potential (39, 80). TGF-␣/EGFR signaling is also significantly elevated at early time points during hepatocarcinogenesis, indicating that TGF-␣ may also be involved in the progression of hepatocellular carcinomas (231). EGFR activation is also related to poor prognosis in carcinomas of the biliary tract (383) . Of note, bile acids are reported to induce cyclooxygenase-2 expression, a well-known inducer of tumorigenesis of many kinds, via EGFR/MAPK signaling in a human cholangiocarcinoma cell line (625).
The EGFR TKI, gefitinib decreased TGF-␣ expression levels and inhibited tumorigenesis in a rat model of cirrhosis that develops hepatocellular carcinoma (482) . Gefitinib also inhibited the development of intrahepatic metastases of hepatocellular carcinoma through inhibition of EGFR transactivation by TNF-␣ and fibronectin (339, 340) . Erlotinib, another EGFR TKI, also prevented the progression of cirrhosis, regressed fibrosis, and blocked the development of hepatocellular carcinomas in animal models, in association with decreased EGFR phosphorylation in hepatic stellate cells (HSCs) and decreased numbers of activated HSC (165).
XI. ROLE OF EGFR IN THE PANCREAS
Both EGFR and its ligands, including EGF, HB-EGF, AREG, and BTC, are expressed in pancreas (139), and EGFR activation increases organ growth due to proliferation of all pancreatic cell types (394, 398, 456, 575) . HB-EGF has been specifically implicated in the development of the endocrine pancreas (islets of Langerhans) (255) (66) . Deficiency of EGFR or its tyrosine kinase activity globally or locally can lead to impaired pancreatic islet development (356, 357) . In addition, activation of the EGFR/PI3K/AKT signaling pathway has a trophic function to prevent islet ␤-cell damage by oxidative stress (327) .
A. EGFR Signaling and Diabetes
EGFR activation by its ligands plays important roles in the pancreatic islets. EGFR signaling pathways are essential for ␤-cell mass expansion in response to a high-fat diet and in pregnancy (200) . EGF is synthesized in the pancreas and increases insulin secretion in mouse pancreatic islets; EGF expression levels are decreased in diabetic animals (285). HB-EGF may not only promote proliferation of preexisting ␤-cells but also may promote ␤-cell differentiation from duct cells, with a resultant increase in ␤-cell mass and improvement of glucose tolerance (273) . Similarly, mice with overexpression of BTC in islets exhibit lower fasting glucose levels and improved glucose tolerance, associated with increased glucose-induced insulin secretion (115) . Epiregulin also stimulates pancreatic cell growth and insulin secretion (275).
B. EGFR Signaling and Pancreas Injury and Fibrosis
EGFR activation by either EGF or betacellulin has been shown to protect against development of acute pancreatitis, in association with pancreatic cell proliferation, decreased inflammatory cytokine/chemokine production, and maintenance of blood flow to the pancreas (113, 309, 550, 590) . However, EGFR activation is also implicated in the development of pancreatic fibrosis resulting from chronic pancreatitis. Activated pancreatic stellate cells are key mediators of pancreatic fibrosis, and ANG II transactivates EGFR to stimulate pancreatic stellate cell proliferation (202) . Furthermore, overexpression of HB-EGF in pancreatic islets stimulates pancreatic stellate cell proliferation via EGFR activation (47, 347).
C. EGFR and Pancreatic Tumorigenesis
Both EGFR and their ligands have been implicated in pancreatic tumorigenesis (634, 644) . Initiation of pancreatic ductal adenocarcinoma is definitively linked to activating mutations in the KRAS oncogene. Oncogenic KRAS upregulates endogenous EGFR expression and activation via the EGFR ligand sheddase, ADAM17. Genetic ablation or pharmacological inhibition of EGFR or ADAM17 effectively eliminates KRAS-driven tumorigenesis (17, 387) , and EGFR TKIs erlotinib and gefitinib inhibit pancreatic tumor growth in mouse models (136, 367). EGFR expression lev-els are inversely related to prognosis in patients with pancreatic cancers (321, 561) . Treatment with erlotinib in combination with gemcitabine in patients with locally advanced/metastatic chemonaive pancreatic cancer patients can produce a small but statistically significant increase in overall survival (490) .
XII. ROLE OF EGFR IN THE REPRODUCTIVE SYSTEM
EGFR is a mediator of both spermatogenesis and oocyte maturation and ovulation, and disruption of EGFR signaling results in impaired reproductive cell development and infertility in both sexes (21, 227, 228, 305, 375, 458, 489, 606) . EGF and other EGF family members, such as TGF-␣, HB-EGF, and AREG, are important mediators of spermatogenesis by both directly modulating Sertoli cells and regulating the function of Leydig cells (429, 436, 498, 529, 530, 558) . Furthermore, an EGFR-ERK signaling pathway negatively regulates the levels of aromatase protein and mRNA, as well as the production of estradiol in response to follicle stimulating hormone (FSH) in immature Sertoli cells to maintain normal testicular development (345) . EGFR activation can also mediate the effect of androgens on Wolffian duct differentiation (197, 198) . Both TGF-␣ and EGFR are expressed throughout embryonic testis development (292), but testes from either EGFR or TGF-␣ knockout mice exhibit normal development except for a subtle reduction of the interstitium in early embryonic stages. Overexpression of TGF-␣ in sexually mature mice impairs testicular descent but does not inhibit normal spermatogenesis (292, 375) . In contrast, overexpression of EGF induces hypospermatogenesis in transgenic mice (606) .
Oocyte development is coordinated by a complex interplay between the oocyte's own developmental program and directives and nutrients from the somatic cell compartment, especially from the granulosa and cumulus cells, and oocyte maturation and cumulus expansion are both necessary for normal ovulation. EGFR is expressed in both cumulus cells and oocytes (including both meiotically competent and incompetent oocytes), and both exogenous EGF and TGF-␣ can induce oocyte maturation and cumulus expansion (124, 171, 191, 557) . In mammals, the midcycle luteinizing hormone (LH) surge triggers a series of changes in the ovarian follicle critical for the ovulation of a fertilizable egg. The LH surge also stimulates expression of AREG, EPR, and BTC, which serve as paracrine mediators to propagate the LH signal throughout the follicle, and inhibition of EGFR signaling suppresses cumulus expansion and oocyte maturation in response to LH treatment (21, 416, 489) . EGFR upregulation by FSH in ovarian follicles during late follicular development is also important for cumulus expansion and oocyte maturation, and EGFR activation by AREG mediates developmental competence during oocyte development (147, 531). Deleting either AREG or EPR leads to delayed onset of oocyte meiotic maturation and reduces cumulus expansion, and deletion of both AREG and EGFR results in impaired ovulation (227). Deletion of EGFR in granulosa cells can also result in impairment of oocyte maturation and ovulation through inhibition of phosphorylation of ERK1/2, p38MAPK, and connexin-43 in response to LH (228).
EGFR signaling plays an important role in mammary gland development and function (103, 551, 560) . Six EGFR ligands: EGF, TGF-␣, amphiregulin, HB-EGF, betacellulin, and epiregulin together with all four ErbB receptors can be detected in mammary gland, with distinct stage-and celltype-specific expression (120, 486) . EGFR is essential for mammary ductal growth and branching morphogenesis, but not for mammary lobulo-alveolar development (601), and normal EGFR signaling is critical for lactation (160, 612) . Interestingly, single gene deletions of EGF, TGF-␣, or amphiregulin had no effect on mammary gland development, but combinatorial double or triple null dams lacking amphiregulin had impaired lactation, indicating functional redundancy of the EGFR ligands, with a predominant role for amphiregulin (319) . EGFR activation by amphiregulin is an important mediator of estrogen and progesterone on induced proliferation and differentiation both before and during puberty (22, 100) and mediates estrogen-and progesterone-induced recruitment of macrophages and eosinophils to the pubertal mammary periepithelium (23). EGF or betacellulin activation of EGFR can modulate prolactin release from the pituitary gland (114, 377) .
Breast cancer is the most common malignancy in women and is a major public health issue (35). The ErbB2 (HER2) subtype of breast cancer representing 25-30% cases is associated with an aggressive phenotype and poor outcome (488) . Treatment with the HER2 antibody Herceptin is effective in patients with HER2 overexpressing breast cancers. Breast cancers with p95HER2 mutation have hyperactive HER2 activity due to its ability to form homodimers maintained by intermolecular disulfide bonds. Breast cancer patients with p95HER2 mutation have poor prognosis (18) . The ErbB family and its ligands may also be involved in the triple-negative basal-type breast cancers. Expression Omnibus indicates that TGF-␣ and NRG2␤, as well as ADAMs and other MMPs responsible for ligand shedding, are expressed at significantly higher levels in estrogen receptor-alpha-negative tumors, while AREG overexpression is found in estrogen receptor-alpha-positive tumors (56, 261, 362) . EGFR inhibitors prevent triple-negative breast cancer growth in a xenograft model (562) and are currently undergoing phase II clinical trials in triple-negative breast cancer and EGFR-positive metastatic breast cancer (247).
There is no direct evidence indicating that EGFR and its ligands are involved in the establishment or maintenance of breast tumor stem cells, but ligand-induced EGFR/ErbB2 signaling may play a role in establishing and maintaining breast cancer stemlike cells (159) . In addition, elevation of EGFR or ErbB2 expression and signaling may contribute to estrogen receptor tyrosine phosphorylation and tamoxifen resistance during clinical treatment (159) .
XIII. ROLE OF EGFR IN TUMORIGENESIS
EGFR and its ligands are abnormally activated or expressed in many human cancers, including colorectal cancer (CRC) and lung cancer. The EGFR signaling pathway is one of the most extensively investigated and the most dysregulated pathway in many human cancers. In addition to typical EGFR signaling pathways as described above, several new pathways have been described recently and may contribute to tumorigenesis and drug resistance.
A. Kinase-Independent Functions
EGFR can mediate cellular processes by physical interaction with other proteins. As noted above, mice with EGFR deletion die either during embryogenesis or shortly after birth, but mice with EGFR kinase activity deficiency (wa2) are viable (318, 355) . The ability of kinase-deficient EGFR to form heterodimers may support tyrosine kinase-independent functions of the receptor. In human cancer cells, kinase-independent EGFR functions autophagic cell death by maintaining intracellular glucose levels through interaction with, and stabilization of, the sodium/glucose cotransporter 1 (SGLT1) (597) . EGFR can interact with PUMA, a p53-upregluated proapoptotic member of Bcl-2 family of proteins (627, 643) constitutively without involvement of its tyrosine kinase activity, leading to PUMA sequestration in the cytoplasm without translocation into mitochondria to initiate apopotosis (643) . In addition, EGFR in plasma membrane lipid raft microdomains can activate AKT without EGFR kinase activity (237). Breast cancer cells with higher levels of EGFR lipid rafts are less sensitive to the EGFR inhibitor gefitinib, and depletion of cholesterol, an essential component of lipid rafts, sensitizes to gefitinib inhibition. Both PI3K and c-Src are localized in the lipid rafts with EGFR (237), suggesting that lipid raft microdomains may serve as a platform for the interactions between EGFR and other signaling molecules to transmit survival signals.
B. Nuclear Mode of EGFR Signaling
Nuclear EGFR has been reported to contribute to transcriptional regulation, cell proliferation, DNA repair, DNA replication, inflammation, and drug resistance in several malignant phenotypes of human cancers (129, 582).
Transportation from cytosol to nucleus
In addition to cell surface and cytosol, EGFR as well as its ligands can be localized within the nucleoplasm and on the inner nuclear membrane (204) . Available evidence suggests that the nuclear EGFR is full length and translocates from the cell surface (313) . Upon ligand binding, EGFR undergoes endocytosis and is internalized through clathrincoated pits. In addition to recycling back to plasma membrane or undergoing lysosome-mediated degradation, a subset of EGFR molecules may be transported into the nucleus. Cell surface EGFRs are trafficked to the nucleus through a retrograde pathway from the Golgi to ER, and then to the inner nuclear membrane (584) . The juxtamembrane region of EGFR harbors a putative nuclear localization signal (NLS) with three clusters of basic amino acids [RRRHIVRKRTLRR (amino acids [645] [646] [647] [648] [649] [650] [651] [652] [653] [654] [655] [656] [657] ] that mediate the nuclear localization of EGFR (229). Through its NLS, EGFR interacts with importins ␣1/␤1, carriers that are critical for nuclear import of macromolecules (300, 312) .
EGFR nuclear transport can be induced by EGFR ligands and inhibited by lapatinib, a dual tyrosine kinase inhibitor for both EGFR and ErbB2. The functions of nuclear EGFR include 1) gene regulation: nuclear EGFR stimulates the expression of cyclin D1 through RNA helicase A, iNOS and COX-2 via STAT3, c-Myc by STAT3 and c-Src, B-Myb through E2F1 and aurora A via STAT5, with resultant proliferation, inflammation, metastasis, drug resistance, and survival. 2) Tyrosine kinase activity: nuclear EGFR increases PCNA stability by phosphorylating the tyrosine residues of chromatin-bound PCNA, leading to cell proliferation and DNA repair. 3) Proteinprotein interactions: through interaction with DNA-dependent protein kinase (DNA-PK), nuclear EGFR promotes DNA repair and subsequent radio-resistance and radioprotection.
Nuclear EGFR may contribute to therapeutic resistance to EGFR inhibitors (294) . In primary breast carcinoma patients, levels of nuclear EGFR inversely correlate with overall survival of breast cancer patients, in association with levels of cyclin D1 and Ki-67, markers of proliferation (315) . Similar inverse correlations between cancer cell nuclear EGFR and poor prognosis are also found in other cancers including oral squamous carcinomas, oropharyngeal carcinomas, and ovarian cancer (443, 610) .
C. Mitochondrial Mode of EGFR Signaling
Upon EGF binding, EGFR can also be translocated to mitochondria and bind to mitochondrial protein cytochrome c oxidase subunit II, leading to activation of survival pathways that contribute to oncogenesis (49). In addition, EGFR mitochondrial localization can be enhanced by rapamycin (an inhibitor of mTOR), apoptosis inducers, c-Src, and EGFR inhibitors (71) . Accumulation of EGFR in the tumor mitochondria could contribute to tumor resistance to drug and apoptosis.
D. EGFR vIII
Amplification and rearrangements of the EGFR gene are frequently found in glioblastoma multiforme. The most common variant is EGFR variant III (EGFR vIII) (125) . Interestingly, EGFR vIII is also found in nuclei and can activate COX-2 gene expression (204) . EGFR vIII is also found in tumor cell mitochondria (71) .
E. Inhibition of EGFR and Cancer Chemotherapy
Activating mutations of EGFR in 15-20% of lung adenocarcinoma provide a molecular basis for the treatment of these patients with EGFR inhibitors, which include small molecules and mAbs (TABLE 2) . Small molecules include gefitinib and erlotinib, which inhibit EGFR tyrosine kinase activity as well as lapatinib which is a dual tyrosine kinase inhibitor for EGFR and ErbB2. The humanized mAbs specifically bind the EGFR extracellular domain. Cetuximab (Erbitux) is used to treat metastatic CRC and NSCLC as well as head and neck cancers while panitumumab (Vectibix) is utilized to treat EGFR-expressing metastatic CRC with disease progression and refractory EGFR-expressing metastatic CRC in patients with wild-type KRAS (506) . In lung adenocarcinomas, EGFR point mutations or in-frame deletions in the intracellular ATP-dependent tyrosine kinase domain lead to constitutive EGFR activation in a ligand-independent manner. In contrast, activating EGFR mutations are located in the extracellular portion in glioblastomas. Therefore, lung adenocarcinoma patients with activating EGFR mutations are sensitive to the small molecule EGFR inhibitor gefitinib, while glioblastoma patients with an activating EGFR mutation are insensitive to it (323) . Although many EGFR mutations have been reported in NSCLC, the most common mutations are an exon 19 deletion, del746-750, and a point mutation, L858R, in exon 21 (475) . In-frame deletions of EGFR may be more sensitive to EGFR inhibitors compared with exon 21 point mutations (98) . Gefitinib and erlotinib may elicit apoptotic cell death through upregulation of the proapoptotic protein BIM in EGFR-mutated cancer cells (187) . Some cancer patients have intrinsic resistance to EGFR TKI treatment. New studies indicate that regardless of EGFR mutation status, low EGFR/MET ratio is associated with resistance to EGFR inhibitor in NSCLC patients (417) . In NSCLC patients treated with erlotinib, NRG-mediated activation of HER3 is the major cause of drug resistance. Therefore, the pan-HER family TKI afatinib provides a better chemotherapy in NSCLC patients because it overcomes NRG-mediated activation of HER3 (623) . Other cancer patients with activating EGFR mutations responded to EGFR TKI initially. However, eventually all tumors recur and develop secondary or acquired resistance to EGFR TKI due to acquired EGFR mutations or nonmutational mechanisms.
Autophagy
EGFR-mediated activation of mTOR inhibits autophagy, and inhibition of EGFR increases autophagy (636) . EGFRinduced phosphorylation of Beclin 1, an important mediator of autophagy, inhibits autophagy, leading to tumor cell growth. In EGFR activating mutants, EGFR tyrosine kinase inhibitors induce autophagy, leading to cell death (205) . 
KRAS/BRAF/MEK1 mutations
PTEN and PIK3CA mutations
PI3K phosphorylates PIP 2 to PIP 3 , leading to activation of the AKT/mTOR signaling pathway. In contrast, PTEN (phosphatase and tensin homolog deleted on chromosome 10) acts as a nonredundant tumor suppressor through its activity of plasma membrane lipid phosphatase, converting PIP 3 to PIP 2 and inhibiting the PI3K/AKT/mTOR signaling pathway. PIK3CA point mutations are found in ϳ4% of lung adenocarcinomas (28). Either activating PI3K mutations or loss of PTEN cause resistance to EGFR TKI.
Other mutations
Mutations in ErbB2 are reported in a very small portion of lung adenocarcinomas (67) . Germline mutation of BIM has been reported in some lung adenocarcinoma patients. Lung adenocarcinomas with these mutations are resistant to EGFR TKI (389) . In addition, EGFR localization in mitochondria and/or in nuclei may also lead to decreased sensitivity to EGFR TKI.
The T790M mutation in exon 20 of EGFR is very rare in untreated tumors but can be detected as a second-site mutation in nearly half of EGFR-mutated lung cancers that have developed acquired resistance to gefitinib or erlotinib. However, this mutation can be lost after an EGFR TKI free period, and patients may therefore again respond to EGFR TKI (491) . Lung adenocarcinoma cell lines harboring an activating EGFR mutation and the T790M mutation have decreased EGFR TKI-mediated upregulation of the proapoptotic mediator, BIM, suggesting that BIM is involved in the acquired resistance to EGFR TKI due to the T790M mutation (108) . Recent data show that T790M mutants may respond to EGFR TKI designed to specifically target this mutant (449).
Small cell transformation
In some NSCLC with activating EGFR mutations, EGFR TKI treatment leads to transformation with features of small-cell carcinomas, which have lost responsiveness to EGFR TKI, but are sensitive to conventional small-cell chemotherapy (491) . In some cases, ErbB2 amplification has also been implicated (626) .
XIV. SUMMARY
This monograph reviews the pleotrophic roles of the EGFR in development, physiology, and pathophysiology. The EGFR and its ligands have been shown to play important roles in development and in regulation of many physiological functions. Furthermore, aberrant expression and/or activation of EGFR has been increasingly implicated in multiple diseases, and the recognition of its important role in carcinogenesis has led to development of targeted drug therapy. New research continues to uncover additional biologic functions for this ubiquitous and fascinating receptor signaling pathway. 
